About venetocla x
BCL-2 inhibitor anticancer medicine
Used for
- Treats chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
- Treats acute myeloid leukemia (AML) with certain other medicines.
Usual adult dose
CLL/SLL: dose is gradually increased over five weeks, then usually 400 mg once daily. AML: gradually increased over three days, then usually 400 mg daily with azacitidine or decitabine, or 600 mg with low-dose cytarabine.
Common side effects
- Low blood-cell counts, including neutropenia and anemia
- Diarrhea, nausea, vomiting, or constipation
- Fatigue and infections
- Tumor lysis syndrome, a potentially life-threatening complication
Important warnings
- Tumor lysis syndrome can occur, especially when starting or increasing doses.
- Serious infections and severe low blood counts may occur.
- Dose changes or extra monitoring may be needed with interacting medicines.
- Do not start, stop, or change treatment without the oncology team.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for 30 days after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment or for one week after the last dose.
Interactions
- Strong or moderate CYP3A inhibitors can greatly increase venetoclax levels.
- CYP3A inducers can reduce effectiveness; avoid strong or moderate inducers.
- Avoid grapefruit, Seville oranges, and starfruit, which can raise drug levels.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.